Amphetamine Stimulant denied as duplicate or overlapping therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for amphetamine stimulant are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies Amphetamine Stimulants as Duplicate Therapy — and How to Appeal

A duplicate-therapy denial means UnitedHealthcare's systems identified that you are already covered for — or have recently filled — another medication it considers therapeutically equivalent to the amphetamine stimulant your prescriber requested. In ADHD pharmacotherapy, this most commonly occurs when a patient is transitioning between formulations (immediate-release to extended-release, or vice versa), when a prescriber issues a new prescription before a prior fill period has elapsed, or when UHC categorizes two distinct amphetamine salts as interchangeable despite clinically meaningful differences in response.

This denial is often a systems error or a misclassification of clinical need, making it one of the more straightforward denial types to overturn with clear prescriber documentation.

## Your Federal Appeal Rights

• Internal appeal (ERISA §503): You are entitled to a full-and-fair review that examines the specific clinical facts of your case, not just the formulary classification. The plan must provide all documents it relied on and the clinical rationale for the denial.
• External review (ACA §2719): If the internal appeal is upheld, you may request independent external review by an accredited IRO within the window stated in your denial letter — typically approximately 180 days from the final internal denial.
• Expedited review: If your condition is urgent (e.g., functional impairment affecting safety at work or school), request expedited processing. Most plans must respond within 72 hours.

## Documentation to Gather

1. Diagnosis confirmation — Records establishing the ADHD or other diagnosis for which the stimulant is prescribed, including any neuropsychological or clinical evaluation. 2. Prior medication history with outcomes — A detailed account of every stimulant tried, the dates of use, the clinical response, and why the current medication is not a true duplicate (different mechanism, formulation, duration of action, or tolerability profile). 3. Prescriber's medical-necessity and differentiation letter — The treating physician should explain specifically why the requested medication is not interchangeable with the one UHC flagged as a duplicate, and why both cannot be reduced to one prescription. 4. Transition documentation — If this is a formulation switch, include notes explaining the clinical reason for the change and confirming the prior medication is being discontinued. 5. Functional-impact documentation — Chart notes or patient-reported outcomes showing the real-world effect of the denied medication versus the supposed duplicate.

## Criteria-Mapping Strategy

Request UHC's current coverage policy and the specific duplicate-therapy rule that was applied. For each criterion, prepare a direct, chart-sourced response showing that the two medications are not equivalent in this patient's clinical context. If the denial stems from a pharmacy-system flag rather than a clinical review, your appeal should state that explicitly and request human clinical review.